Please note that the information in this Safety log is correct at the time of publication. Clinicians should always refer to the most up to date information.

Copyright © Midlands and Lancashire Commissioning Support Unit

Medicines Safety Assurance Tool

June 2020

To request this safety tool, or for more information about this tool, to make a comment, or share a safety issue please contact micsu.medicines-safety@nhs.net



Cyproterone acetate: new advice to minimise risks of meningioma 29 June 2020 Risk of meningioma with cyproterone acetate increases with increasing cumulative dose	Proposed action Newsletter Practice audit/search	☐ Optimise Rx/ScriptSwit☐ Other (please specify)	cch
	Action taken		
	Status Unassigned ▼	Action due date	Date completed
<u>Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents</u> 29 June 2020	Proposed action Newsletter Practice audit/search	☐ Optimise Rx/ScriptSwit☐ Other (please specify)	cch
Remain vigilant for signs and symptoms of bleeding complications during treatment with DOACs (apixaban, dabigatran, edoxaban, rivaroxaban), especially in patients with increased bleeding risks.			
	Action taken		
	Status Unassigned	Action due date	Date completed

Please note that the information in this Safety log is correct at the time of publication. Clinicians should always refer to the most up to date information.

Copyright © Midlands and Lancashire Commissioning Support Unit

Medicines Safety Assurance Tool

June 2020

To request this safety tool, or for more information about this tool, to make a comment, or share a safety issue please contact micsu.medicines-safety@nhs.net



Summary of Product Characteristics updates

Constella (linaclotide) 290 micrograms hard capsules

Urticaria has been added to SPC as an uncommon adverse reaction.

Erythroped (erythromycin ethylsuccinate) SF 250mg/5ml

SPC updated to warn erythromycin should not be given to patients with a history of QT prolongation (congenital or documented acquired QT prolongation) or ventricular cardiac arrhythmia, including torsades de pointes.

Evra (ethinylestradiol/norelgestromin) transdermal patch

Anaphylactic reaction has been added as a rare adverse event.

GlucaGen (glucagon) Hypokit 1 mg

The tip cap of the syringe included in the GlucaGen HypoKit no longer contains natural rubber latex.

Kenalog (triamcinolone acetonide) Intra-articular/Intramuscular Injection

Blurred vision has been added as adverse effect and SPC updated to advise that visual disturbance may be reported with systemic/topical corticosteroid use and if a patient presents with such symptoms, they should be considered for referral to an ophthalmologist for evaluation.

Ovranette (ethinylestradiol/ levonorgestrel) tablets

SPC contraindicates concomitant use with ombitasvir/paritaprevir/ritonavir, dasabuvir, glecaprevir/pibrentasvir & sofosbuvir/velpatasvir/voxilaprevir owing to significant increases in ALT levels, and warns that oestrogens may induce or exacerbate hereditary & acquired angioedema.

Proposed action		
☐ Newsletter	☐ Optimise Rx/ScriptSv	vitch
☐ Practice audit/search	\square Other (please specify	')
Action taken		
Status	Action due date	Date completed
Unassigned ▼		

Copyright © Midlands and Lancashire Commissioning Support Unit

Medicines Safety Assurance Tool

June 2020

To request this safety tool, or for more information about this tool, to make a comment, or share a safety issue please contact micsu.medicines-safety@nhs.net



Rigevidon (ethinylestradiol, levonorgestrel) tablets

SPC updated to warn ethinylestradiol, levonorgestrel products are contraindicated for concomitant use with the medicinal products containing lecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir.

Seroquel (quetiapine) tablets

SPC now details that in patients presenting with extensive rash, exfoliative dermatitis, fever, lymphadenopathy and eosinophilia, treatment should be withdrawn immediately as it may be suggestive of a severe cutaneous adverse reaction, such as Stevens-Johnson syndrome.

Sevodyne (buprenorphine) transdermal patch – all strengths

SPC updated to warn that for all patients, prolonged use may lead to drug dependence, even at therapeutic doses; and risks are increased in individuals with current or past history of substance misuse disorder or mental health disorder.

Solu-Medrone (methylprednisolone) 40 mg Powder for Injection

Cow's milk allergy has been removed from the list of contraindications, and from the special warnings and precautions for use section. The list of excipients has been updated, as has the in-use shelf-life and storage conditions of the reconstituted product.

Tenoretic 100 mg/25 mg and Tenoret 50 mg/12.5 mg (atenolol/chlortalidone) film coated tablets

Choroidal effusion has been added to SPC as ADR of unknown frequency. It is noted that sulphonamide/sulfonamide derivative drugs (such as chlorthalidone) can cause this idiosyncratic reaction which can lead to visual field defect, transient myopia and acute angle-closure glaucoma.

<u>ViePax (venlafaxine hydrochloride) XL prolonged-release tablets – all strengths</u>

SPCs updated to include stress cardiomyopathy as an undesirable effect of treatment with unknown frequency.

Please note that the information in this Safety log is correct at the time of publication. Clinicians should always refer to the most up to date information.

Copyright © Midlands and Lancashire Commissioning Support Unit

Medicines Safety Assurance Tool

June 2020

To request this safety tool, or for more information about this tool, to make a comment, or share a safety issue please contact micsu.medicines-safety@nhs.net



Xalacom eye drops, solution (timolol)

Hallucinations has been added as an adverse drug reaction.

Zebinix (eslicarbazepine) 200mg tablets

SPC now advises that as bioavailability (AUC and Cmax) has been shown to be comparable with whole tablets, for patients who can't swallow, the tablets may be crushed and mixed with water or soft foods such as apple sauce immediately prior to administration.